MUMBAI: Sun Pharma Advanced Research Company Ltd. (SPARC) announced the receipt of a complete response letter from the US Food and Drug Administration (FDA) on its New Drug Application (NDA) for Venlafaxine Extended-release tablets, 300mg, an anti-depressant product. A complete response letter is a communication from the FDA to companies that an NDA cannot be approved in its present form.
In the complete response letter, the FDA has requested for some additional studies related to efficacy and safety. Based on the FDA's feedback, SPARC is evaluating the commercial viability of this product, says a company statement.
Sun Pharma Advanced Research Company, is the research arm of Sun Pharma, engaged in research and development of drugs and delivery systems.
Anda sedang membaca artikel tentang
USFDA seeks more data on Sun Pharma's anti-depressant drug
Dengan url
http://cegahkeropostulang.blogspot.com/2013/12/usfda-seeks-more-data-on-sun-pharmas.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
USFDA seeks more data on Sun Pharma's anti-depressant drug
namun jangan lupa untuk meletakkan link
USFDA seeks more data on Sun Pharma's anti-depressant drug
sebagai sumbernya
0 komentar:
Posting Komentar